Status of oncology drugs with a conditional approval: A cross‐sectional comparison of the Food and Drug Administration and Health Canada

Ähnliche Einträge

• Do drugs approved via expedited approval pathways have therapeutic advantages? A systematic review and meta‐analysis
  von: Ashleigh Hooimeyer, et al.
  Veröffentlicht: (2026)
• Common pitfalls in oncology drug applications aiming for conditional marketing authorization
  von: Sinan B. Sarac, et al.
  Veröffentlicht: (2025)
• Pharmacovigilance of obeticholic acid: An analysis of the Food and Drug Administration Adverse Event Reporting System database
  von: Qining He, et al.
  Veröffentlicht: (2025)
• Estimating the prevalence of potential and actionable drug‐gene interactions in Irish primary care: A cross‐sectional study
  von: L. Johnson, et al.
  Veröffentlicht: (2024)
• Cardiovascular events of Bruton's tyrosine kinase inhibitors: A real‐world study based on the United States Food and Drug Administration Adverse Event Reporting System database
  von: Zeng‐Xiang Zhao, et al.
  Veröffentlicht: (2024)